Benitec Biopharma Limited (NASDAQ:BNTC - Get Free Report) crossed below its 50 day moving average during trading on Friday . The stock has a 50 day moving average of $14.27 and traded as low as $12.47. Benitec Biopharma shares last traded at $13.14, with a volume of 74,946 shares changing hands.
Analyst Upgrades and Downgrades
BNTC has been the topic of a number of analyst reports. HC Wainwright restated a "buy" rating and set a $28.00 target price on shares of Benitec Biopharma in a research report on Monday, May 19th. JMP Securities reiterated a "market outperform" rating and issued a $20.00 price target on shares of Benitec Biopharma in a research note on Thursday, May 15th. Seven research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of "Buy" and a consensus target price of $23.83.
Read Our Latest Report on BNTC
Benitec Biopharma Stock Performance
The company has a debt-to-equity ratio of 0.01, a quick ratio of 14.80 and a current ratio of 14.80. The company has a market cap of $344.93 million, a P/E ratio of -8.70 and a beta of 0.37. The stock's fifty day moving average price is $14.27 and its two-hundred day moving average price is $12.92.
Benitec Biopharma (NASDAQ:BNTC - Get Free Report) last released its earnings results on Wednesday, May 14th. The biotechnology company reported ($0.24) earnings per share for the quarter, topping the consensus estimate of ($0.36) by $0.12. As a group, equities analysts predict that Benitec Biopharma Limited will post -1.48 earnings per share for the current year.
Institutional Trading of Benitec Biopharma
Institutional investors and hedge funds have recently modified their holdings of the business. Franklin Resources Inc. raised its stake in Benitec Biopharma by 269.0% during the fourth quarter. Franklin Resources Inc. now owns 2,939,287 shares of the biotechnology company's stock worth $37,123,000 after acquiring an additional 2,142,643 shares in the last quarter. Janus Henderson Group PLC grew its holdings in shares of Benitec Biopharma by 198.5% during the 4th quarter. Janus Henderson Group PLC now owns 2,616,427 shares of the biotechnology company's stock valued at $33,268,000 after purchasing an additional 1,739,904 shares during the last quarter. Adage Capital Partners GP L.L.C. increased its position in Benitec Biopharma by 134.4% during the 4th quarter. Adage Capital Partners GP L.L.C. now owns 1,972,524 shares of the biotechnology company's stock worth $24,913,000 after purchasing an additional 1,131,129 shares in the last quarter. Infinitum Asset Management LLC increased its position in Benitec Biopharma by 435.7% during the 1st quarter. Infinitum Asset Management LLC now owns 1,125,000 shares of the biotechnology company's stock worth $14,636,000 after purchasing an additional 915,000 shares in the last quarter. Finally, Suvretta Capital Management LLC lifted its stake in Benitec Biopharma by 1.5% in the 4th quarter. Suvretta Capital Management LLC now owns 8,960,009 shares of the biotechnology company's stock valued at $113,165,000 after purchasing an additional 130,956 shares during the last quarter. 52.19% of the stock is currently owned by institutional investors.
About Benitec Biopharma
(
Get Free Report)
Benitec Biopharma Inc, a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference-based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Benitec Biopharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Benitec Biopharma wasn't on the list.
While Benitec Biopharma currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
